Hirose H, Aoyama M, Oshima K, Udo K, Kobayashi S, Adachi N, Nonaka T, Yamada T
Gan To Kagaku Ryoho. 1982 Dec;9(12):2216-21.
Twenty-two cases of non-operable hepatocellular carcinoma (HCC) were treated with three types of chemotherapy mainly with Adriamycin (ADM). In the group (A), one shot intraarterial infusion of 100 mg ADM into the hepatic artery (9 cases), group (B), one shot intraarterial infusion of 30 mg ADM (3 cases), and group (C), 20-60 mg of systemic administration of ADM (10 cases) were examined. The therapeutic effects and side effects were studied comparatively among these three groups. In terms of tumor regression, RR was 4 cases (44.4%), and MR was 4 (44.4%) in group (A), and PR was 1 (10%) in group (C). The average survival time was 8.3 months (5 cases are still alive) in group (A), 5.7 months in group (B), and 4.2 months in group (C), respectively As side effects, alopecia was found 100% in (A), 33% in (B); leukocytopenia was found 100% in (A), 33% in (B); but no serious complication due to leukocytopenia was observed in any of them. One shot of 100 mg of ADM intraarterial infusion therapy seemed to be superior in therapeutic effects against HCC over other therapies.
22例无法手术的肝细胞癌（HCC）患者接受了三种以阿霉素（ADM）为主的化疗方案。A组，经肝动脉一次性动脉内注入100mg阿霉素（9例）；B组，经肝动脉一次性注入30mg阿霉素（3例）；C组，全身给药阿霉素20 - 60mg（10例）。对这三组的治疗效果和副作用进行了比较研究。在肿瘤消退方面，A组的完全缓解（RR）为4例（44.4%），部分缓解（MR）为4例（44.4%），C组的部分缓解（PR）为1例（10%）。A组的平均生存时间为8.3个月（5例仍存活），B组为5.7个月，C组为4.2个月。作为副作用，A组脱发发生率为100%，B组为33%；A组白细胞减少发生率为100%，B组为33%；但三组均未观察到因白细胞减少引起的严重并发症。经肝动脉一次性注入100mg阿霉素的治疗方案在治疗肝癌方面似乎比其他治疗方法效果更好。
